Inflammatory bowel disease (IBD) and C. difficile infection (CDI) affect millions worldwide, causing significant suffering and long term chronic disability resulting in escalating financial burden on healthcare providers. Conventional therapies have proven to be ineffective and typically only manage disease symptoms, rather than cure. In this project, the SBRC in collaboration with CHAIN Biotech aim to develop the synthetic biology tools to enable strain engineering; and development of Clostridia for targeted peptide secretion. The engineered strains will be used as a delivery vehicle for the secretion of anti-microbial and anti-inflammatory therapeutic peptides in the human gut. This novel approach is referred to as a live biotherapeutic product (LBP) where the engineered microbe is the product, secreting the therapeutic peptides targeting gut diseases like IBD and CDI.